Year: 2024
Type: article
Study design: Observational Study
Abstract: Introduction: COVID-19 patients in critical condition can suffer a lot of inflammation and oxidative stress, making their prognosis poor. Clinicians propose that HDIVC can be an additional therapy, as its antioxidant and immunomodulatory properties may help patients. Objective: This study aimed to examine how HDIVC affects the outcomes of critically ill patients with COVID-19. Materials and Methods: A prospective cohort study was conducted at Department of Pulmonology, Saidu Medical College and Saidu Group of Teaching Hospital Swat, Pakistan, from January, 2024 to June, 2024. Only ill COVID-19 patients treated with usual procedures and either HDIVC or no HDIVC were studied. The team looked at measurable measurements of inflammation and how patients recovered. Results: After HDIVC administration, the ICU death rate, time spent in the ICU, and mechanical ventilation time were reduced. Among the inflammatory markers, including CRP, D-dimer, and ferritin, levels decreased more in the HDIVC group than in the control group. Conclusion: HDIVC appears to make treatment safer and more effective for critically ill COVID-19 patients. Repeated larger studies should confirm the results found in this research.
DOI: 10.53555/spt1qp81
Author: Akhtar Ali Khan
Institutions: Saidu Teaching Hospital, Saidu Medical College
Language: English
Subfield: Nutrition and Dietetics
Field: Nursing
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4412845520